(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers - 2Improving as a Pioneer: Examples from My Vocation
- 3Satellite space quiz: What's orbiting Earth?
- 4Asia's Noteworthy Destinations: A Voyager's Aide
- 5Step by step instructions to Keep up with Ideal Oral Cleanliness at Home
- Get away from the Tedious Drudgery: Go into Business Today!
- The Solution to Individual budget: Dominating Cash The board
- Vote In favor of Your Favored Language Learning Applications
- Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- A Couple of Modest Guitars for 2024
- Portable Installment Answers for Independent ventures
- Vote in favor of Your Number one BWM Vehicles
- Forget 'Outer Banks.' These Gen Z-ers just want to watch 'M*A*S*H*' and 'Gilmore Girls.'
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
